CureMetrix and Philips Fighting Breast Cancer Together
Curemetrix entered the ring and wins a pilot contract with Philips. You can learn more about the process and outcome of the Philips event here.
CureMetrix is committed to the advancement of technology that will improve cancer survival rates worldwide. We are focused on developing the next generation of medical image analysis technology that healthcare providers and patients can confidently rely on.
Using our patent-pending algorithm, we are developing an adjunct, precision tool for mammography. Our goal is to equip radiologists with the objective, data-driven answers they need to support patients and their healthcare team as they make decisions about their breast cancer screening, treatment and diagnosis. At CureMetrix, we believe that providing radiologists with the most advanced technology to support their evaluation of mammograms will lead to improved clinical outcomes, reduced healthcare costs and increased assurance that patients are getting the highest standard of imaging care available.
Research with our investigational CureMetrix image analysis platform demonstrates its potential to:
Results from preliminary studies across thousands of images suggest that our algorithm can reduce false positive rates that may lead to unnecessary follow-up procedures and undue anxiety among patients. LEARN MORE
We are developing powerful technology that could enable health care providers to hone in on even the most microscopic changes more quickly and accurately than ever before. LEARN MORE
Our algorithm has the potential to help physicians track the rate of change of growth of lesions over time, which may enable more informed follow-up and treatment decisions. LEARN MORE
We seek to develop technology that will identify and classify the most suspicious anomalies and discard the verifiably benign ones, which may help radiologists improve their triage process and focus where it matters most. LEARN MORE
The CureMetrix image analysis platform is the foundation that, if successful, may allow us to extend our technology across modality, anatomy and disease states. LEARN MORE